DaVita shares slid 4.4% in pre-market trading to $218 after the kidney dialysis company reported second-quarter results that on the surface surpassed Wall Street expectations but raised questions about the quality of those gains.
The company reported adjusted earnings per share of $4.02, topping the consensus estimate of $3.84. Revenue came in at $3.55 billion compared with the $3.49 billion estimate. Despite the headline beat on both top and bottom line metrics, investors focused on deteriorating economics on a per-treatment basis.
Margin pressures stood out. Revenue per treatment dropped by about $2 sequentially, while patient care costs per treatment remained elevated through the first half of the year. Those dynamics reduced the apparent strength of the reported results and were a central factor behind the negative pre-market reaction.
Management reconfirmed, rather than raised, its full-year 2026 adjusted EPS guidance range of $14.10 to $15.20. The midpoint of that range is $14.65, which is below the analyst consensus of $14.88. The guidance reconfirmation failed to meet elevated investor expectations and contributed to the stock's decline.
Analyst commentary added to the caution. Barclays kept an Equalweight rating but raised its price target to $224 from $218, a move that suggested the stock was trading near or above fair value prior to the latest drop. After the earnings-driven weakness, the share price was closer to Barclays' target and to an independent fair value estimate of $216.52 than to the 52-week high of $247.49.
Market-wide conditions offered little explanation for the move. The S&P 500 and the Dow Jones both rose modestly on the day, while the Nasdaq was essentially flat, indicating that DaVita's pre-market weakness was driven by company-specific results rather than broader market or sector selling.
There was a positive operational datapoint: treatment volume grew 56 basis points year-over-year, aided by lower-than-expected patient mortality. However, management and investors judged that the volume increase was insufficient to offset the impact of lower revenue per treatment and persistent patient care cost pressures.
Takeaway: A second-quarter earnings beat masked softer per-treatment revenue and persistent cost pressures, management held its full-year guidance steady below consensus, and analysts maintained a cautious stance. Those factors combined to push the stock toward pre-market lows and closer to recent price targets and fair value estimates.